Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ICML 2019 | DLBCL research to watch

Georg Lenz • 20 Jun 2019
ICML 2019
B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Polatuzumab vedotin
POLARIX

Georg Lenz, MD, University of Münster, Münster, Germany, gives his insight into the latest diffuse large B-cell lymphoma (DLBCL) research to watch. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Georg Lenz

Update from the Lenz lab in Münster
1:29
Update from the Lenz lab in Münster
Georg Lenz • 20 Jun 2019
Can we improve on R-CHOP for the frontline treatment of DLBCL?
1:26
Can we improve on R-CHOP for the frontline treatment of DLBCL?
Georg Lenz • 20 Jun 2019
The unmet need in DLBCL
0:43
The unmet need in DLBCL
Georg Lenz • 18 Apr 2016
The importance of recgonizing different DLBCL subtypes
1:08
The importance of recgonizing different DLBCL subtypes
Georg Lenz • 9 Jun 2016

Related Videos

Time to third-line treatment after BR +/- acalabrutinib in previously untreated MCL: ECHO analysis
2:24
Time to third-line treatment after BR +/- acalabrutinib in previously untreated MCL: ECHO analysis
Georg Lenz • 10 Dec 2025
Two-year follow-up from ZUMA-2: safety and efficacy of brexu-cel in R/R MCL
1:13
Two-year follow-up from ZUMA-2: safety and efficacy of brexu-cel in R/R MCL
Georg Lenz • 10 Dec 2025
A novel cell model of pirtobrutinib-tolerant persister cells in mantle cell lymphoma
5:31
A novel cell model of pirtobrutinib-tolerant persister cells in mantle cell lymphoma
Georg Lenz • 10 Dec 2025
Retrospective study on outcomes and safety of covalent BTK inhibitors for the treatment of MCL
2:32
Retrospective study on outcomes and safety of covalent BTK inhibitors for the treatment of MCL
Georg Lenz • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals